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Palliative lung RT: ASTRO CPG 61Practical Radiation Oncology: April-June 2011reviews on the following topics: (1) dose fractionation in thoracic external beam radiotherapy
(EBRT); (2) clinical utility of initial and salvage endobronchial brachytherapy (EBB); and (3) use of
concurrent chemotherapy (CC) with palliative thoracic radiotherapy. Practice guideline recommen-
dations were produced and are contained herein.
Results: Studies suggest that higher dose/fractionation palliative EBRT regimens (eg, 30 Gy/10
fraction equivalent or greater) are associated with modest improvements in survival and total
symptom score, particularly in patients with good performance status. As these improvements are
associated with an increase in esophageal toxicity, various shorter EBRT dose/fractionation
schedules (eg, 20 Gy in 5 fractions, 17 Gy in 2 weekly fractions, 10 Gy in 1 fraction), which provide
good symptomatic relief with fewer side effects, can be used for patients requesting a shorter
treatment course and/or in those with a poor performance status. No defined role for EBB in the
routine initial palliative treatment of chest disease has been demonstrated; however, EBB can be a
reasonable option for the palliation of endobronchial lesions causing obstructive symptomatology
including lung collapse, or for hemoptysis after EBRT failure. The integration of concurrent
chemotherapy with palliative intent/fractionated radiotherapy is not currently supported by the
medical literature.
Conclusion: This Guideline is intended to serve as a guide for the use of EBRT, EBB, and CC in
thoracic palliation of lung cancer outside the clinical trial setting. Further prospective clinical
investigations with relevant palliative endpoints into the respective roles of EBB and CC/targeted
therapy in the thoracic palliation of lung cancer are warranted, given the current state of the medical
literature in these areas.
© 2011 American Society for Radiation Oncology. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.Introduction
Many patients with metastatic lung cancer (LC), and
selected patients with locally advanced disease, are
routinely treated with thoracic radiotherapy with palliative
intent to relieve tumor-related symptoms (hemoptysis,
bronchial obstruction, cough, shortness of breath, and
chest pain) and to improve health-related quality of life
(QoL).1 The majority of randomized controlled trials and
meta-analyses/systematic reviews have focused on the
questions of external-beam radiation therapy (EBRT) dose
fractionation and the use of endobronchial brachytherapy
(EBB) in the initial or salvage palliative management
(either alone or in conjunction with other treatment
modalities) of lung cancer. In addition, the use of
concurrent chemotherapy (CC) with palliative radiothera-
py has been the subject of various investigations. Practice
guidelines and consensus statements have been previously
prepared to provide guidance to practitioners and patients
with regard to treatment options.1-8 In addition, investiga-
tions into treatment selection from the practitioner,9
patient,10 and economic viewpoints11 have been under-
taken to provide guidance.
Given the issues regarding the heterogeneity of
therapeutic approaches for the thoracic palliation of LC
with radiotherapy, the American Society for Radiation
Oncology (ASTRO) Clinical Affairs and Quality Com-
mittee convened a Task Force of experts in the field of LC
to develop a guideline on the use of radiotherapy in the
thoracic palliation of LC with EBRT, EBB, and CC with
radiotherapy. Guideline recommendations, contained
herein, were based on the results of a systematic reviewof the literature and supplemented by the expert opinion
from the members of the Task Force.Methods and materials
Process
In conjunction with an ongoing international palliative
LC workshop consensus project,12 the Guidelines Subcom-
mittee of the ASTRO Clinical Affairs and Quality
Committee (CAQC) identified the use of palliative
radiotherapy as it is applied to LC as a high-priority topic
needing an evidence-based guideline.Accordingly, a project
proposal to the ASTRO Board of Directors was prepared by
2 ASTRO members of the international palliative lung
workshop consensus working group (G. Rodrigues and B.
Movsas) and was approved in June 2009. The Board of
Directors authorized creation of a TF to study issues related
to the use of radiotherapy in the treatment of LC and
approved its membership, which included 7 recognized
experts in LC radiation oncology, 1 in radiation oncology/
pulmonology/community practice, 1 representative from the
Guidelines Subcommittee of the CAQC, 1 medical
oncologist, and 1 radiation oncology resident.
The TFwas to review and synthesize currently available
evidence to develop a clinically practical, evidence-based
guideline to help radiation oncologists and LC patients to
determine the appropriate use of EBRT, EBB, and
concurrent palliative chemoradiotherapy for palliative
intent LC patients. The members of the Task Force divided
into 3 subgroups to address separate questions based upon
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communications by conference calls and e-mail, the TF
completed the systematic literature review, reviewed
manuscripts, created evidence tables, and formulated the
practice guidelines contained herein. The initial draft of
the manuscript was reviewed by 3 expert reviewers (see
Acknowledgment) and then ASTRO legal counsel, and
was subsequently placed on the ASTRO Web site
(during the month of December 2010) for a period of
public comment. Upon integration of this feedback, the
document was then submitted to the ASTRO Board of
Directors for their final review and approval in January
2011. The TF sought to adhere to the American Medical
Association's Physician Consortium for Performance
Improvement guidance for measure development and
recent calls for reform of the guideline process during
the preparation of this practice guideline.13,14 The
ASTRO Guidelines Subcommittee will monitor this
guideline and initiate an update when appropriate.
Literature search
A literature search strategy was developed around the
3 practice guideline questions of EBRT dose fraction-
ation, indications for EBB, and use of CC with palliative
intent radiotherapy. All search strategies were performed
on PubMed assessing possible articles from 1966 to
March 1, 2010. In particular, identification of randomized
controlled trials (RCTs) or of other prospective clinical
trial evaluations, if RCTs were unavailable, was the focus
of the literature search. Reference lists for published
practice guidelines, consensus statements, metaanalyses,
and systematic reviews were cross-referenced with search
strategies to ensure a complete set of manuscripts and
abstracts for review by the TF. All abstracts were initially
reviewed by GR for an assessment of study relevance
before a formal collection of manuscripts/abstracts for TF
review and data synthesis. The following key words and
MeSH headings were used for the respective research
questions: (1) What is the optimal dose/fractionation
schedule for thoracic EBRT in patients with lung cancer?
(radiotherapy/radiation, dosage/dose fractionation, pallia-
tive, quality of life, lung neoplasms, clinical trial,
metaanalysis, RCT, and review, 174 articles); (2) What
is the role of EBB alone or in conjunction with other
modalities (including external beam radiation) in both the
initial and salvage palliative management of lung cancer?
(lung neoplasms, brachytherapy, palliative, clinical trial,
metaanalysis, practice guideline, RCT, 21 articles); and
(3) What is the role of chemotherapy administered
concurrently (chemotherapy drug delivery on same days
for some or all radiation fractions) with radiation for the
palliation of lung cancer? (antineoplastic combined
chemotherapy protocols/agents, palliation, lung neo-
plasms, radiation/radiotherapy, chemoradiation/chemora-
diotherapy, 109 articles).Results
What is the optimal dose/fractionation schedule
for thoracic palliative EBRT in patients with LC?
Guideline statement
Since 1985, multiple prospective randomized trials of
different dose/fractionation schedules have shown that
thoracic palliative EBRT can alleviate thoracic symptoms
in patients with locally advanced or metastatic non–small
cell lung cancer (NSCLC) who are not candidates for
curative therapy. Studies suggest that higher dose/
fractionation EBRT regimens (eg, 30-Gy/10-fraction
equivalent or greater) are associated with modest improve-
ments in survival and total symptom score, primarily in
patients with good performance status. As these improve-
ments are also associated with a increase in side effects or
adverse effects, such as radiation esophagitis, various
shorter fractionation schedules (eg, 20 Gy in 5 fractions,
17 Gy in 2 weekly fractions, 10 Gy in 1 fraction) have
been demonstrated to provide good symptomatic control
with fewer side effects, and can be used for patients
requesting shorter treatment courses and/or with poor
performance status.Narrative
Patients requiring palliative thoracic RT present with
symptoms that are caused by locoregional growth of
tumor that may be safely and adequately encompassed by
an RT field. Indications for thoracic EBRT include, but
are not limited to: hemoptysis, cough, chest pain,
dyspnea, obstructive pneumonia, dysphagia related to
esophageal compression, superior vena cava syndrome,
hoarseness, or stridor. Symptoms caused by malignant
pleural effusion, lymphangitic carcinomatosis, and multi-
lobar parenchymal disease typically are not suitable for
palliative thoracic EBRT.
There have been 14 RCTs15-28 published to date
addressing the question of the optimal EBRT dose schedule
to palliate symptomatic advanced LC. A comprehensive
review of these trials was completed in 20064 and updated
in 200929 with no change in conclusions, by the Cochrane
Collaboration. A total of 3708 patients were randomized in
the 14 trials, and of these 3576 were evaluable. Descriptive
features of these trials are provided in Table 1.
Overall, the 14 studies were heterogeneous by the dose
regimens used, the performance status, the age of patients
accrued, and the selection and reporting of outcomes,
leaving the Cochrane group able to perform a narrative
synthesis only. Significant heterogeneity of symptom
assessment and toxicity endpoints were observed; howev-
er, in general, all studies showed a beneficial effect of the
palliative RT, without any specific schedule being favored.
In the studies that conducted QoL analyses (XRT),24-26
there were no major differences noted between schedules.
Table 1 Randomized controlled trials assessing palliative lung radiotherapy fractionation
Study Y Radiotherapy schedules compared Evaluable
patients
(n)
Survival a by regimen
(P = NS unless
specified)
Symptom control by
regimen (P = NS
unless specified)
Simpson 1985 40 Gy/20 F daily continuous/4 wk
vs 30 Gy/10 F/2 wk vs 40 Gy/
10 F/4 wk, split course
316 6.2 mo vs 6.9 mo vs 6.4 mo No difference
Teo 1988 45 Gy/18 F/3.5 wk vs 31.2 Gy/
4 F/4 wk
273 20 wk vs 20 wk Better with 45 Gy,
P = .012
MRC 1991 30 Gy/10 F/2 wk or 27 Gy/
6 F/2 wk or 17 Gy/2 F/8 d
369 177 d vs 179 d No difference
MRC 1992 17 Gy/2 F/8 d vs 10 Gy/1 fraction 235 100 d vs 122 d No difference
Abratt 1995 35 Gy/10 F/2.5 wk vs
45 Gy/15 F/3.75 wk
84 8.5 mo vs 8.5 mo No difference
MRC 1996 36 or 39 Gy/12 or 13 F/2.5 wk vs
17 Gy/2 F/8 d
509 1. 9 mo vs 2.7 mo, P = .03 No difference
Rees 1997 17 Gy/2 F/8 d vs 22.5 Gy/5 F/5 d 216 23% vs 18% (1 y) No difference
Reinfuss 1999 50 Gy/25 F/5 wk (conventional) vs
40 Gy/10 F daily (split course with
4 wk gap) vs delayed
radiotherapy (20–25 Gy/4 or
5 F when symptomatic).
240 18% vs 6% vs 0%,
P b .05 (2 y)
No assessment
of symptoms
Nestle 2000 32 Gy/16 F twice daily/10 d vs
60 Gy/30 F/6 wk
152 36% vs 38% (1 y) No difference
Bezjak 2002 20 Gy/5 F/1 wk vs 10 Gy/1 F 230 6 mo vs 4.2 mo, P = .03 Better for 20 Gy on Lung
Cancer Symptom
Scale, P = .009
Sundstrom 2004 17 Gy/2 F/8 d vs 42 Gy/15 F/
3 wk vs 50 Gy/25 F/5 wk
407 6.8 mo vs 7.0 mo vs
8.2 mo
No difference
Erridge 2005 30 Gy/10 F/2 wk vs 10 Gy/1 F 148 23 wk vs 28 wk Better for 30-Gy arm,
P = .05
Kramer 2005 30 Gy/10 F/2 wk vs 16 Gy/2 F/8 d 297 20% vs 11%, P = .03 (1 y) No difference
Senkus-Konefka 2005 20 Gy/5 F/1 wk vs 16 Gy/2 F/8 d 100 5.3 mo vs 8.0 mo, P = .016 No difference
F, fraction; Gy, gray; NS, nonsignificant.
a Survival given as median value or percentage at specific timepoint.
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generally mild for the majority of patients in all studies, a
consistent finding was that higher-dose regimens were
associated with increased toxicity, particularly esophagitis.
Late toxicity in the form of radiation myelopathy, although
rare, was noted in 4 trials.17,18,20,25 Seven trials that
described response endpoints found no differences
between regimens.15-17,19,22,23,28 Overall the Cochrane
conclusions were as follows: (1) there was no strong
evidence favoring 1 EBRT schedule over another with
respect to efficacy of palliation; (2) acute toxicity was
greater with higher-dose regimens; (3) patients with better
performance status might have a survival benefit with the
higher dose regimens (5% at 1 year and 3% at 2 years); and
(4) radiation myelopathy may be associated with some
regimens (eg, 17 Gy/2 fractions), requiring appropriate RT
planning. A 2008 review30 and a recent 2010 review31
have arrived at similar conclusions.
Fairchild et al30 carried out a quantitative pooling of data
abstracted from each study's text, figures, and tables. Theyreported a statistically higher survival and lower total
symptom score with the higher dose schedules (30 Gy/10
fractions equivalent or higher—eg, 30–35 Gy/10 fractions,
36–45Gy/12–15 fractions [3 Gy/day], or 50–60 Gy/25–30
fractions [2 Gy/day]), at the cost of increased esophageal
toxicity. Of interest, Macbeth and Stephens32 grouped 13 of
14 trials by radiobiological equivalency (RBE), comparing
the following: (1) RBE-equivalent regimens in all groups of
patients; (2) RBE-equivalent regimens in patients with poor
performance status; and (3) RBE-differing regimens in
better performance status patients. For group 1, the
investigators found similar efficacy and survival irrespec-
tive of radiation regimen. For group 2, they concluded that a
single 10-Gy fraction is an effective and suitable treatment.
For group 3, they found only 1 study16 with any significant
differences in symptom control, and 2 trials20,22 with
significantly better survival for high dose (30-Gy/10-
fraction equivalent or greater) radiation regimens.
In summary, the clinical trial evidence has demonstrat-
ed that higher dose radiation treatment fractionations (30-
64 G. Rodrigues et al Practical Radiation Oncology: April-June 2011Gy/10-fraction equivalent or greater) are associated with
improvements in total symptom score and survival (but at
the cost of some increased side effects, such as radiation
esophagitis), primarily in patients with good performance
status. The specific high-dose fractionation schedule to
optimize the therapeutic ratio between improvements in
total symptom score/survival and minimization of normal
tissue effects such as radiation esophagitis is currently
unknown. Similarly, the impact of newer treatment
technologies such as intensity-modulated radiation therapy
(IMRT), image-guided radiation therapy (IGRT), as well
as the integration of pretreatment imaging (eg, 18fluor-
odeoxyglucose–positron emission tomography [18FDG-
PET]) in the context of thoracic palliative radiation therapy
has not yet been clearly defined. These dose fractionation
and technology considerations should be explored in
future prospective clinical trials of patients receiving
palliative lung radiotherapy.
Various shorter fractionation schedules (eg, 20 Gy in 5
fractions, 17 Gy in 2 fractions, and 10 Gy in 1 fraction)
also provide good symptomatic relief and can be used for
patients requesting shorter total treatment courses and also
for patients with poor performance status. In addition, in
the setting of patients actively receiving palliative
chemotherapy with new thoracic symptoms, shorter
fractionation schedules may be more easily integrated
between chemotherapy cycles without chemotherapy
delays for patients with thoracic symptomology that
could benefit from thoracic radiotherapy.
What is the role of EBB alone or in conjunction
with other modalities (including EBRT) in both
the initial and salvage palliative management
of LC?
Guideline statement
There is currently no randomized or metaanalysis-
based evidence to recommend EBB alone or in conjunc-
tion with other palliative therapies (EBRT, chemotherapy,
Nd:YAG laser) in the routine initial palliative management
of endobronchial obstruction resulting from LC. If there is
already evidence of collapsed lung resulting from central
endobronchial disease, initial EBB in conjunction with
EBRT can be considered because of observed increased
reexpansion rates in a randomized clinical trial. EBB also
remains a reasonable option in the palliative management
of a patient with endobronchial lesion causing obstruction
or hemoptysis who has previously received thoracic
EBRT. Continuing prospective clinical trials in the areas
of initial and salvage EBB are encouraged to better define
the role of this modality in the palliation of LC patients.Narrative
In some patients with LC, it is possible to treat a tumor
in the bronchus through the placement of endobronchialcatheters. This allows delivery of radiation to the luminal
aspect of the tumor and, thereby, opening of the bronchial
obstruction. The goal of such therapy is the relief of
endobronchial symptoms such as cough, shortness of
breath, and hemoptysis. EBB cannot be used to treat
extrabronchial disease or disease in the lung parenchyma.
The literature search identified 6 RCTs (Table 2) that
have evaluated the palliative role of EBB in LC.32-39 One
matched pair analysis40 and an additional RCT41 were
reported in the context of radical dose external beam
radiotherapy. These 2 additional studies did not report on
any palliative endpoints and therefore were not considered
further in this practice guideline.
Mallick et al33 randomized 45 patients with non–small
cell lung cancer (NSCLC) into 3 treatment arms. Arm A
patients received EBRT of 30 Gy/10 fractions and EBB of
16 Gy/2 fractions at 1 cm, delivered once weekly. Arm B
received EBRT of 30 Gy/10 fractions and EBB to 10 Gy/1
fraction at 1 cm. Arm C received no EBRT and EBB of 15
Gy/1 fraction at 1 cm. When analyzed by groups, there
were no differences in response rates for dyspnea, cough,
or hemoptysis; however, the study may have been
underpowered to answer these questions.
Sur et al34,35 reported the results of an RCT on
inoperable Stage III NSCLC patients who were not suited
for chemoradiation treatment and who had luminal
disease. Initially patients were treated with EBRT of 30
Gy/10 fractions, 36 Gy/18 fractions, or 40 Gy/20 fractions,
at the discretion of the treating physician. Patients were
randomized to receive 2 EBB treatments of 6 Gy/fraction
at 1 cm, delivered once weekly (Group A) or EBRT of 20
Gy/10 fractions (Group B). The improvement in quality of
life was similar in both groups, although duration of
symptom-free survival was shorter with EBB (median 77
days for EBB vs 129 days for EBRT, P = .009).
Langendijk et al36 randomized 95 patients with
endobronchial NSCLC to receive EBRT alone (arm 1) or
EBRT and EBB (arm 2). Patients receiving EBRT either
received a radical (60 Gy) or palliative (30 Gy) radiation
dose, at the discretion of the treating physician. Patients in
arm 2 received EBB of 15 Gy/2 fractions at 1 cm,
delivered once weekly. The median survival was similar
for the 2 groups (8.5 months for EBRT alone, and 7
months for EBRT plus EBB, P = .21). Rates of lung re-
expansion, defined radiographically or spirometrically,
were improved with EBB (35% for EBRT alone vs 57%
for EBRT plus EBB, P = .01). Correspondingly, a
temporary improvement in the palliation of patient-
reported dyspnea was noted with the addition of EBB to
EBRT over EBRT alone (P = .02). This study suggested
that EBB with EBRT may be used in selected patients with
severe dyspnea resulting from endobronchial tumor
obstruction in the main bronchus.
Chella et al37 randomized 29 patients with NSCLC
involving the central airway and not eligible for surgery,
chemotherapy, or EBRT. Fifteen patients (group 1) had
Table 2 Randomized controlled trials assessing endobronchial brachytherapy
Author Y Disease description Patient
no.
Treatment Median
FU
Survival a Symptom endpoints Complications
Mallick 2006 Untreated inoperable
stage III NSCLC with
endobronchial disease
15 EBRT 30 Gy/10F+HDREB
8 Gy @ 1 cm q1w × 2
6 mo NR No significant differences
in dyspnea, cough, or
hemoptysis reported
FH n = 1
15 EBRT 30Gy/10F+HDREB
10Gy @ 1 cm × 1
6 mo NR
15 HDREB 15 Gy @ 1 cm × 1 6 mo NR
Sur 2002 Inoperable, stage III proven
NSCLC, luminal disease,
no prior treatment
65 All patients: EBR: 30 Gy/10 F;
or 36 Gy/18 F; or 40 Gy/20 F
followed by either:
12 No significant differences
in dyspnea, cough, or
hemoptysis reported
NR
2004 NR EBRT: 20 Gy/10 F over 2 wk; or 12 29.4% (1 y)
NR HDREB: 12 Gy/2 F over 2 wk @ 1 cm 12 29.7% (1 y)
Mean HDREB dose: NR P = NS
Langendijk 2001 Inoperable stage IIIB
NSCLC with tumor in
main or lobar bronchus
47 Radical EBRT (60 Gy) or
palliative EBRT (30 Gy)
NR 8.5 mo (95%
CI = 5.4–11.6)
Temporary improvement in
patient-reported dyspnea
for HDREB arm
FH 13%
48 Radical or palliative EBRT +
HDREB of 7.5Gy @ 1 cm q1w × 2
NR 7.0 mo (95%
CI = 5.3–8.9)
P = .02 FH 15%
Mean HDREB dose: NR P = NS P = NS
Chella 2000 NSCLC involving central
airway, SQ 72%
15 Nd-YAG: 25–45 W using
pulses up to 1.2 s to a
mean total of 1850 J
17.8 NR Mean symptom-free survival
increased from 2.8 to 8.5 mo
by addition of HDREB
0%
14 Nd-YAG + HDREB of 5 Gy
@ 0.5 cm q1w × 3
P b .05 7%
Mean HDREB dose: NR
Stout 2000 Inoperable, histologically
proven NSCLC, SQ 82%
50 EBRT: 30 Gy/8 F over 10–12 d NR 9.4 mo/38% (1 y) Improved symptom
palliation for EBRT (83%)
vs HDREB (59%)
6%
49 HDREB: 15 Gy @ 1 cm × 1 8.2 mo/22% (1 y) P = .03 8%
Mean HDREB dose: NR P = .04
Huber 1995 Histologically proven
stage I–IV lung cancer,
IIB/IV 80%, SQ 49%
44 HDREB (4): 3.8 Gy @ 1 cm q1w × 4 30 4.2 mo/11.4% (1 y) No significant differences
in dyspnea, cough, or
hemoptysis reported
22%
49 HDREB (2): 7.2 Gy @ 1 cm q3w × 2 4.4 mo/20.4% (1 y) 21%
Mean HDREB dose: HDREB (4)/(2),
13.4 ± 5.2 Gy/13.7 ± 4.4 Gy
P = NS
CI, confidence interval; EBRT, external beam radiotherapy; FH, fatal hemopytsis; HDREB, high-dose-rate endobronchial brachytherapy; Gy, gray; F, fraction(s); J, joule; Nd-YAG, neodymium-doped yttrium:
aluminium garnet; NR, not reported; NSCLC, non–small cell lung cancer; pts, patients; SQ, squamous histology.
a Survival reported either as median value or as percentage at specific time point.
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laser debulking followed by EBB. The EBB was given 15
to 18 days after neodymium-doped yttrium:aluminium
garnet (Nd-YAG) to a dose of 15 Gy/3 fractions at 0.5 cm,
delivered once weekly. The mean duration of symptom-
free and progression-free survival increased from 2.8 to
8.5 months and 2.2 to 7.5 months favoring EBB,
respectively (P b .05, each).
Stout et al38 randomized 99 untreated patients with
stage III NSCLC and symptoms of endobronchial
obstruction to EBB of 15 Gy/1 fraction (49 patients) at
1 cm or EBRT 30 Gy/8 fractions (50 patients). A
statistically significant improvement in overall survival
and patient-reported symptom palliation was seen for
EBRT vs EBB (1-year survival 37% vs 22%, P = .04; 83%
palliation vs 59%, P = .03).
Huber et al39 performed an EBB dose optimization
study in 93 patients primarily with advanced LC. Group 1
received EBB of 15.4 Gy/4 fractions at 1cm, delivered
weekly. Group 2 received EBB of 14.4 Gy/2 fractions at
1 cm, delivered over a 3-week interval. There were no
significant differences between the groups in terms of local
control, fatal hemopytsis, or 1-year overall survival. The
study did not evaluate relief of symptoms or QoL.
In total, there are only 426 patients represented on the
aforementioned studies, with no individual RCT having
sufficient numbers to draw definite conclusions. It is
evident that the addition of EBB does not improve
survival for patients with LC (Table 2). In fact, the only
trial reviewed that reports a significant difference in
survival for LC patients between EBRT and EBB favors
EBRT.38 A recent Cochrane systematic review of 13
RCTs came to similar conclusions: EBRT is superior to
EBB for the initial palliation of symptoms, and there is no
added benefit to EBRT plus EBB over EBRT alone7 or
with EBB versus EBRT and Nd-YAG laser. These
findings are likely due to the fact that EBRT is indicated
in most cases because of extrabronchial bulky disease that
cannot be addressed with EBB. In addition, a broncho-
scopic procedure is performed for catheter placement as
part of an EBB procedure. At the time of this procedure,
the lesion can be debulked/bypassed with ablative
procedures and/or stenting and, in all cases, must be
opened to pass the EBB catheter. These procedures would
tend to reduce or eliminate the usefulness of integrating
EBB with EBRT.
EBB remains a reasonable therapeutic maneuver, when
feasible, in patients who would have failed previous EBRT
and now present with recurrent bronchial obstruction or
hemoptysis and/or in selected patients presenting with
initial lung obstruction in the setting of nonmetastatic
endobronchial disease. The goal of the EBB in the latter
group would be to potentially re-expand the lung before or
in conjunction with radical dose radiotherapy, if clinically
appropriate. No ideal EBB dose prescription regimen was
identified in the literature with regard to these 2 clinicalscenarios (salvage therapy after EBRT and initial lung
obstruction with nonmetastatic disease). Further prospec-
tive clinical trials defining the specific indications/criteria
for use of EBB and the optimal dose fractionation
prescription regimens to be used are encouraged.What is the role of chemotherapy administered
concurrently with radiation for the palliation
of LC?
Guideline statement
At this time, there is no added benefit for the use of
chemotherapy concurrently with radiation therapy (RT) in
the palliation of thoracic symptoms in lung cancer patients.
To date, there is 1 randomized phase III study directly
addressing this issue.42 This study showed that, although
the addition of chemotherapy to RT increased the overall
response rate, this small benefit came at the cost of
significant increased toxicity with no significant improve-
ment in overall survival, progression-free survival, or
symptom palliation. Most of the remainder of the studies
have been early phase I studies involving a heterogeneous
group of patients with a paucity of prospective quality of
life data. In the context of patients receiving palliative
chemotherapy, the goal should be to optimally sequence or
integrate courses of chemotherapy and RT in a noncon-
current fashion to palliate lung symptoms as clinically
indicated. The use of concurrent chemoradiation should
primarily be reserved for clinical trials.
Narrative
Recently, systemic chemotherapy has become a
standard of care for patients with metastatic or recurrent
NSCLC. Several randomized studies have demonstrated
that, when compared with best supportive care (BSC),
chemotherapy not only significantly improves survival but
also reduces symptoms and enhances QoL. Moreover, in
1 study comparing chemotherapy to BSC, significantly
fewer patients randomized to chemotherapy required
palliative radiation (49% vs 79%), and the median time
to radiation was significantly delayed in the chemotherapy
arm (29 weeks vs 4 weeks).43 At the same time, in patients
with locally advanced NSCLC, intact PS, and limited
weight loss, several RCTs have shown an advantage for
the use of concurrent chemoradiation over sequential
therapies.44,45 These studies demonstrated an improve-
ment in overall survival, presumably due to the synergistic
effects of combining chemotherapy and radiation, but at
the cost of increased toxicity particularly severe esopha-
gitis. In light of these concerns, it is reasonable to study the
benefit/risk ratio of adding chemotherapy concurrently
with thoracic radiation in the palliative setting for LC. A
MEDLINE search identified several prospective studies
that address this issue42,46-53; these studies are summa-
rized in Table 3.
Table 3 Prospective clinical trials assessing concurrent chemotherapy with palliative lung radiotherapy
First author Year Phase Stage a N RT Chemo MS (mo) CR/PR Gr 3 + NH toxicity/QOL Comment
Ball 1997 III “Advanced" 200 20 Gy/5 F ± 6 (RT) vs Overall response
29% vs 16%
P = .035
Increased toxicity with
chemo (N/V, esophagitis
[12% vs 3%], stomatitis,
skin reaction)
Randomized study
FU 1 mg/m2/d × 5 d 6.8 (chemo-RT) Studied QOL
P = .36 No significant
difference in OS,
DFS, or palliation
Micheal 2005 I IIIB/IV 24 40 Gy/20 F Dose escalated
weekly PV to
13.5 4%/61% No gr 3+ esophagitis
or lung
PET response
89% infield
V = 30 mg/m2;
P = 20 mg/m2
Significant decrease
in cough on LCSS
Has QOL (LCSS)
Hoffman 2002 I II/III/IV 36 2 Gy/d
x 5–7 wk
V 15 mg/m2 d 1,
8 q 3 wk × 2
C AUC 1.5
escalated to AUC 3
13.5 17%/52% 22% esophagitis ∼25% severe
NH toxicity11% Lung
(8% gr 5) (8% gr 5 toxicity)
Siewert 2007 I III/IV 30 40–66 Gy Prem
200–600 mg/m2
q 21 d × 2 or
Prem 500 mg/m2 +
escalating C
(AUC 4–6)
q 21 d × 2
NA 7%/27% 7% esophagitis Preparation for
stage III study
Jeremic 1999 II IV 50 14 Gy/2 F
(d 1, 8)
C 300 mg/m2 d 1, 29 7 6%/21% 19% esophagitis “Elderly" (N70 y)
etoposide 50 mg/m2 9% lung
d 1–21 and d 29–42 (6% improvement
in symptoms)
(continued on next page)
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68 G. Rodrigues et al Practical Radiation Oncology: April-June 2011There are several limitations regarding the data
available. The majority of these studies are early phase I
(safety) studies, with relatively small numbers of patients.
At this time, there appears to be only 1 RCT focusing on
this issue42; however, this RCT used fluorouracil, an agent
currently not commonly used in systemic therapy in LC. A
second challenge relates to the degree of patient
heterogeneity included in these prospective studies.
There is variation in the staging procedures used, patient
stage, performance status, degree of weight loss, age, and
gender. There is considerable variation regarding the
actual treatments administered, both with respect to RT
(dose and schedule), as well as chemotherapy (type, dose,
and schedule). Some of the studies used a hypofractionated
palliative radiation approach (14–17 Gy/2 fractions),
whereas others used high doses of radiation over
approximately 6 to 7 weeks.47,48 The systemic agents,
dosing, and timing used varied considerably among
studies. Another major limitation in most studies is the
absence of routine patient-reported symptom or QoL
instruments for assessment of the palliative response.
Despite these limitations, careful review of these
studies demonstrates some important lessons. There has
been only 1 large RCT (n = 200).42 Patients received 20
Gy/5 fractions and were randomized either to thoracic RT
alone or to RT plus fluorouracil (1 g/m2/day for 5 days by
continuous infusion). Eligibility stipulated a diagnosis
of NSCLC with disease “unsuitable for either attempted
curative resection or radical RT or recurrent intrathoracic
cancer outside any previously radiated volume.” The
overall radiographic response rate was higher in RT plus
fluorouracil (29% vs 16%, P = .035). However, there was
no significant improvement in disease-free survival,
overall survival, or palliation of symptoms. Rather,
patients treated with combined modality therapy had
significantly more acute toxicity, including nausea and
vomiting (P = .01), esophagitis (P = .0003), stomatitis
(P = .0005), and skin reactions (P = .003). There were no
significant differences between the 2 arms in any of the
thoracic symptoms or QoL scales. Although the improved
radiographic response suggests an interaction between
radiation and fluorouracil in NSCLC, this combination did
not translate into better palliation.
Other smaller (typically phase I) studies also question
the relative benefit versus the risk of adding chemotherapy
concurrently with RT for the palliation of LC. Hoffman et
al47 designed a phase I study to determine the maximal
tolerated dose of carboplatin when administered in
combination with a fixed dose of vinorelbine and
concurrent RT in patients with advanced NSCLC. EBRT
was administered in daily fractions of 2 Gy over 5 to 7
weeks. With respect to toxicity, 8 of 36 treated patients
(22%) had severe (grade 3/4) esophagitis. Of even more
concern, 4 patients developed pneumonitis 4 to 7 months
after completing therapy, which was fatal in 3 patients.
Overall, approximately 25% of patients developed severe
Palliative lung RT: ASTRO CPG 69Practical Radiation Oncology: April-June 2011nonhematologic toxicity, and 8% had grade 5 toxicity. In
this study, the overall radiological response rate was 52%
and the median survival was 13.5 months. By comparison,
in a larger study of 240 patients with stage III disease who
were “also unsuitable for a radical RT approach,” Reinfuss
et al reported a similar (12-month) median survival using
RT (50 Gy/25 fractions) without any chemotherapy.49
Similarly, Jeremic et al50 studied 50 “elderly” patients
(N70 years) with stage IV NSCLC who were treated with a
combination of 14 Gy/2 fractions concurrently with
carboplatin (200 mg/m2 days 1 and 29 and etoposide 15
mg/m2 on days 1–21 and 29–42). In this study, there was a
19% rate of grade 3 esophagitis and a 9% rate of grade 3
lung toxicity. Median survival was 7 months and the
overall response rate was 27%. As previously pointed out,
without a comparison arm, it is difficult to evaluate
whether there is a benefit to this combined approach
compared with radiation or chemotherapy alone, yet there
does appear to be an increase in the rate of toxicity.
Moreover, there are virtually no data for more
“modern” chemotherapy typically used in the new
millennia, such as premetrexed, as well as taxanes.
However, some lessons are available by extrapolation:
1. Bevacizumab in combination with XRT is unwise
and unproved. The Southwestern Oncology Group
(SWOG) has suspended a trial attempting to integrate
this agent into full dose radiation, in combination
with etoposide and cisplatin, in part because of the
possibility of excess hemoptysis and other life-
threatening complications. In limited SCLC, the
addition of bevacizumab to standard chemoradiation
has led to tracheal–esophageal fistulas.54
2. Gemcitabine is a potent radiosensitizer with marked
mimetic effect, with reports of severe esophagitis
and pneumonitis.55
3. In a CALGB study in poor-risk patients receiving
definitive RT after induction chemotherapy, the
addition of gefitinib to RT does not seem to
exacerbate in-field toxicities. This approach yielded
a median survival of nearly 20 months.56
Overall, studies to date have suggested that the benefit/
risk ratio does not support the addition of chemotherapy
concomitantly with radiation for the palliation of LC,
primarily because of concerns regarding toxicity and no
clear evidence that symptom palliation is improved. It is
possible, though, that optimization of the radiation tech-
nique and attention to the nature and schedule of syste-
mic therapy may, in the future, improve the therapeutic
benefit. For example, Schwarzenberger et al51 studied 26
patients with advanced NSCLC (stage III/IV) who were
treated with hypofractionated RT (5 Gy per week × 10)
concurrently with dose escalated docetaxel (10–45 mg/m2
per week). The RT technique used a “field within a field”
approach in which the gross tumor volume received 3 Gyper fraction and the clinical target value 2 Gy per fraction.
With this approach, the investigators were able to fully
escalate the dose of the chemotherapy with limited
toxicity. There were no grade 3/4 nonhematologic
toxicities among 19 evaluable patients. Moreover, the
investigators observed an excellent response rate involving
14 of 19 (74%) evaluable patients, 3 of whom subse-
quently underwent surgery and were downstaged to stage
I. The median survival in this study was also promising at
17 months. The chemotherapy agent of the study was
administered 24 hours before the RT fraction to take
advantage of the “peak sensitizing effect.” Although this
was an early phase I study with the limitations noted
above, it suggests that novel approaches may exist to
combine standard chemotherapy (and newer biological
agents) and radiation in this setting to enhance the
therapeutic ratio. Thus, although there is no proven role
for combining chemotherapy concurrently with RT for
palliation of LC, this strategy requires further study and
could potentially become a promising approach in the
future to help optimize the risk/benefit ratio. It is critical
that validated QoL measures be included in such studies
since the primary goal of these studies is palliation. At this
time, the standard of care in the palliation of LC remains
chemotherapy alone and/or thoracic radiotherapy alone
without concurrent chemotherapy. However, the goal
should be to optimally sequence and integrate the courses
of chemotherapy and RT to palliate lung symptoms as
clinically indicated. Use of concurrent chemoradiation
should primarily be reserved for clinical trials.Conclusion
The medical literature suggests that patients with good
performance status may benefit from higher-dose/fraction-
ation EBRT palliation (30-Gy/10-fraction equivalent or
greater) because of the observed modest observed survival
benefit. No defined role for endobronchial brachytherapy
for the routine initial palliative treatment of chest disease
has been demonstrated; however, endobronchial bra-
chytherapy remains an option for the palliation of
endobronchial lesions causing obstructive symptomatolo-
gy in the EBRT failure scenario or in locally advanced
nonmetastatic cancer patients with endobronchial disease
who require lung re-expansion before or in conjunction
with radical RT. The integration of concurrent chemother-
apy with palliative intent/fractionated RT is not currently
supported by the medical literature. However, integration
of palliative chemotherapy and RT in a nonconcurrent
fashion is important for the optimal palliation of lung
cancer patients with thoracic symptoms. Recent (and
ongoing) changes in pretreatment lung cancer imaging,
systemic agents, and radiation planning/delivery technol-
ogies (eg, IMRT, IGRT, and stereotactic body RT) will
require continued prospective evaluation to optimize
70 G. Rodrigues et al Practical Radiation Oncology: April-June 2011patient clinical and health-related QoL outcome in this
patient population.
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